Valneva SE provides update on ACIP Recommendation for its chikungunya vaccine IXCHIQ (6.79)
- Co announced that during its regular meeting on April 16, the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) updated its recommendation for use of Valneva's single-dose chikungunya vaccine IXCHIQ® for the prevention of disease caused by the chikungunya virus (CHIKV). ACIP maintained its current recommendation for IXCHIQ for persons aged =18 years traveling to a country or territory where there is a chikungunya outbreak. Additionally, it may be considered for persons aged =18 years traveling or taking up residence in a country or territory without an outbreak but with elevated risk for U.S. travelers if planning travel for an extended period of time e.g., six months or more.
- The ACIP also voted to recommend a precaution related to the use of IXCHIQ in persons aged =65 years. This precaution is a response to an ongoing investigation by the CDC of six cases of serious adverse events (SAEs), including five hospitalizations, among persons aged 67-86 years after vaccination with IXCHIQ.
- ACIP also noted that for individuals aged =65 years, vaccination with IXCHIQ might be indicated in certain higher-risk settings (e.g., outbreak), given the known risks for severe chikungunya disease and hospitalization in this age group.